Pfizer and Astellas report groundbreaking results in muscle-invasive bladder cancer trial

Eli Lilly’s orforglipron outshines oral semaglutide in landmark diabetes trial

The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints

Star Health & Allied Insurance rolls out 32 free primary care clinics across 9 states

The initiative, funded entirely under the company’s CSR programme, is expected to reach over a million lives

Pfizer bags rull FDA nod for BRAFTOVI combination in aggressive colorectal cancer

BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results

Novo Nordisk unveils weight-loss data from REDEFINE 4 trial

CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide

BNB Plus’ Biopharma subsidiary LineaRx lands major LineaDNA orders

The announcement follows a record-setting $1.2 million accelerated LineaDNA order

Promise Bio launches frontier Epiproteomic Innovation Grant to supercharge biotech R&D

The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform

iRegene doses first US Parkinson’s patient, launches landmark MSA trial in China

The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration

AbbVie to invest $380 million in new North Chicago manufacturing facilities

Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade

Eris Lifesciences partnership with Natco Pharma for Semaglutide launch in India

The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape